Immunomodulation With Eltrombopag in ITP

NCT04812483 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

2

Enrollment

OTHER

Sponsor class

Conditions

Primary Immune Thrombocytopenia (ITP)

Interventions

DRUG: Eltrombopag (Revolade®)
DRUG: standard therapy (without eltrombopag): HD-DXM

Sponsor

University Children's Hospital Basel

Collaborators

[object Object]
[object Object]
[object Object]